Spontaneous aggregation of the anti-viral MAVS protein in systemic lupus erythematosus: a possible cause of excessive type I interferon production
- 683 Downloads
KeywordsSystemic Lupus Erythematosus Peripheral Blood Mononuclear Cell Systemic Lupus Erythematosus Patient Interferon Signature Interferon Production
Patients with systemic lupus erythematosus (SLE) often have evidence of excessive type I interferon production, with increased interferon levels and activation of interferon-inducible genes (interferon signature). The mitochondrial adaptor protein MAVS (also known as IPS1, VISA or CARDIF) is a key intermediary in the RIG-I pathway, where viral RNA triggers a conformational change in RIG-I, leading to MAVS activation and activation of IKK and TBK1, with subsequent interferon production driven by IRF-3 and NFκB activation and translocation. A recent report using in vitro methods demonstrated that MAVS may form large prion-like aggregates which might stimulate IFN-I activation in a potent and prolonged fashion . We wondered whether such aggregates might be detectable ex vivo in SLE patients, and whether they might play a role in the sustained increased production of IFN-I. The aim was to determine whether aggregated MAVS protein is present in blood cells from SLE patients.
Peripheral blood mononuclear cells (PBMC) were isolated from 17 patients fulfilling ACR criteria for SLE, and from nine controls. Thirty million PBMC were lysed and pellets loaded onto semi-denaturing detergent vertical 1.5% agarose gels. After electrophoresis, the proteins were transferred to Immobilon membranes for immunoblotting with anti-MAVS antibody or anti-β-actin.
This is the first report of aggregated MAVS in human cells. The relationship of this abnormality to disease needs further investigation, but suggests the possibility that prolonged and increased IFN-I production could result from MAVS aggregation, with the formation of poorly degradable prion-like protein that could signal IFN-I production for prolonged periods.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.